Recent Updates
Recently added Catalysts

Sulfadoxine pyrimethamine

Phase 3

Malaria in Pregnancy | Small molecule | Infectious Disease |Novartis AG|Last Updated: Nov 4, 2022

Development status

Highest phase Phase 3
Registered trials 2 across 2 sponsors since Mar 2021

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedACTIVE_CONTROLLEDBiomarker
Total Trials1
Total Enrollment250

FDA Designations

No designations recorded

Clinical trial landscape

Sulfadoxine pyrimethamine · 1 trial · 1 indication

Phase 3 1
NCT04783051Comparison of ISTp- PYRAMAX-US-RDT to IPTp-SP to Prevent Malaria in Pregnant Women in DRC (ULTRAPYRAPREG)Malaria in Pregnancy
COMPLETED250 Analytics
PHASE3COMPLETED
Comparison of ISTp- PYRAMAX-US-RDT to IPTp-SP to Prevent Malaria in Pregnant Women in DRC (ULTRAPYRAPREG)
Malaria in PregnancyUnlock trial analytics

Study Endpoints

Primary Endpoints

The proportion of asymptomatic malaria in the 2 study arms
6 months

Asymptomatic malaria is defined as the presence of Pf diagnosed by an us-RDT in the peripheral blood and a T°≤38°C

The proportion symptomatic malaria in the 2 study arms
6 months

Symptomatic malaria is be defined as the presence of Pf diagnosed by an us-RDT in the peripheral blood and a T°≥38°C

The proportion of parasitic densities in the 2 study arms
6 months

Parasite density is assessed by the quantification of Pf parasites in the peripheral blood of asymptomatic/symptomatic women by a thin blood smear examined by standard malaria microscopy

The proportion of anemia in the 2 study arms
6 months

Anemia is defined as a level of hemoglobin (Hb) \<10g/dl

The incidence of spontaneous abortions or intrauterine deaths in the 2 study arms
6 months

Intrauterine death is defined to describe the death of the offspring in the uterus

The proportion of fetal morbidities in the 2 study arms
6 months

Fetal morbidity is defined as any of the following: Preterm birth (birth before 37 weeks gestation) and low-birth-weight (birth weight under 2,500 grams)

The proportion of the neonatal and early neonatal mortality of the offspring in the 2 study arms
28 days

The early neonatal mortality is defined as infant death at birth or within 7 days of life; And the neonatal mortality is defined as infant death within the first 28 days of life

Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposePREVENTION

Treatment Arms

ArmTypeDescription
IPTp-SPACTIVE_COMPARATORThe IPTp-SP group will be pregnant women who will receive the standard regimen recommended by the Malaria National Control Program (MNCP) at week 16, 28, 32 and 36 of their pregnancy
ISTp-US-PyEXPERIMENTALThe ISTp-US-Py group will comprise pregnant women who will be screened monthly from the beginning of the 2nd trimester with ultra-sensitive -RDT and who will be treated with Pyramax® if the test is positive

Interventions

NameTypeDescription
Sulfadoxine pyrimethamineDRUGIntermittent Preventive Treatment in pregnant women with Sulfadoxine-Pyrimethamine
PyramaxDRUGIntermittent screening using ultra-sensitive malaria Rapid Diagnostic test and treatment using Pyronaridine - Artesunate (PYRAMAX®)
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexFEMALE
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: 1. Gestation ≥16 weeks; 2. Age: ≥18 years; 3. Residence within the health facility catchment area; 4. Willing to adhere to study requirements and to deliver at the health facility. 5. Willing to provide written informed consent; if the woman is illiterate, she can choose an impa...

Countries:Democratic Republic of the Congo
Unlock Eligibility Criteria